CARSGEN-B (02171) saw its shares increase by more than 3% in early trading. At the time of writing, the stock had risen by 1.90% to HK$21.50, with a turnover of HK$19.47 million.

The company recently announced that abstracts summarizing the results of the Investigator-Initiated Trials (IIT) for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN-B's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company intends to begin a Phase Ib registration clinical trial for R/R B-NHL in 2026.